1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Tibet Rhodiola Pharmaceutical Holding Co. Class A

Tibet Rhodiola Pharmaceutical Holding Co. Class A

600211.SS
Tibet Rhodiola Pharmaceutical Holding Co. Class ACN flagShanghai Stock Exchange
37.05
CNY
-0.53
- -
11.94BMarket Cap
Tibet Rhodiola Pharmaceutical Holding Co. Class A
600211.SS
(Shanghai Stock Exchange)

Recent

price

37.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.15
4.05
4.62
5.39
6.12
5.22
3
2.99
3.14
5.41
4.27
6.61
7.92
9.71
8.7
9.25
8.87
Revenue per Share
0.09
0.08
0.12
0.1
0.08
0.35
0.75
0.75
0.66
1.35
1.3
0.65
1.15
2.48
3.26
2.91
3.11
Basic EPS, GAAP
- -
0.04
0.2
0.94
-0.62
0.47
0.91
-1.69
0.81
1.9
0.64
-0.18
2.28
3.23
2.97
3.07
-0.11
Free Cash Flow per Basic Share
- -
- -
0.01
0.05
0.04
0.04
0.1
0.26
0.21
0.29
0.59
0.41
0.3
1.53
1.56
1.9
2
Dividend per Share
0.32
0.39
0.5
0.56
0.57
0.87
1.46
1.88
2.16
4.06
3.77
3.99
4.89
5.87
7.72
8.76
8.54
Book Value per Share
0.96
1.11
1.27
1.34
1.36
1.68
-2.57
2.74
3.42
5.82
5.02
6.74
8.07
9.79
11.65
11.64
12.53
Tangible Book Value per Share
268
267
265
260
273
265
265
306
327
232
322
323
323
323
322
322
321
Basic Weighted Avg Shares
1,111
1,079
1,221
1,402
1,668
1,383
797
916
1,028
1,256
1,373
2,139
2,555
3,134
2,807
2,982
2,843
Sales/Revenue/Turnover
1.69
1.14
1.82
1.62
1.89
5.33
24.71
28.55
31.24
27.46
33.42
26.95
29.44
39.21
39.75
32.53
36.68
Operating Margin (%)
16
16
16
17
16
12
56
77
77
77
78
81
69
68
75
80
- -
Depreciation Expense
24
21
31
27
21
92
198
230
216
312
418
209
370
801
1,051
938
995
Net Income, GAAP
19.33
9.97
4.82
20.39
23.78
14.66
10.19
10.44
10.78
10.01
10.56
16.41
19.01
9.79
8.25
11.88
8.39
Effective Tax Rate (%)
2.12
1.9
2.5
1.94
1.26
6.63
24.89
25.08
20.98
24.87
30.45
9.77
14.48
25.55
37.46
31.46
35.02
Profit Margin (%)
120
128
176
201
205
292
-963
548
826
1,031
1,017
1,072
1,686
2,218
2,803
2,997
2,785
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
12
2
1
1
- -
- -
- -
LT Debt
324
355
385
402
414
486
658
2,045
2,257
2,447
2,588
2,645
3,031
3,374
3,952
4,137
4,198
Total Equity
3.76
2.44
4.25
3.54
4.48
11.34
27.25
16.61
13.13
13.05
16.11
16.46
17.88
29.35
24.82
18.38
19.71
Return on Invested Capital (%)
16.03
11.4
15.94
14.77
9.3
33.9
59.46
48.01
33.13
37.04
38
13.52
19.14
35.57
40.37
28.69
29.83
Return on Capital (%)
33.67
21.8
25.92
19.58
14
47.77
64.35
47.77
33.67
37.89
38.79
16.69
25.79
46.14
47.96
35.31
38.68
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
273
517
693
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
322
322
322
Market Capitalization
11,917
12,204
11,803

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
3,570
4,065
4,222
Cash, Cash Equivalents & STI
2,625
3,126
3,027
Accounts Receivable, Net
527
491
718
Inventories
134
149
149
Total Current Liabilities
767
1,053
1,437
Payables & Accruals
- -
- -
- -
ST Debt
273
517
693
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
32.07%
9.99%
4.69%
Free Cash Flow
-179.55%
-287.43%
3.3%
Net Income, GAAP
36.88%
32.8%
-10.78%
Sales/Revenue/Turnover
11%
18.73%
6.23%
Total Cash Common Dividend
90.87%
74.31%
21.72%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
704
910
561
631
2,807
2025
712
939
892
- -
2,982
2026
724
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.97
- -
- -
- -
3.26
2025
0.84
- -
- -
- -
2.91
2026
0.93
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
1.56
2025
0.27
- -
- -
- -
1.9
2026
- -
- -
- -
- -
- -
Similar Companies
Neuphoria Therapeutics Inc. (NEUP)
BioSyent Inc. (RX.V)
Welcia Holdings Co., Ltd. (WLCGF)
Evolus, Inc. (0K16.L)
JW Lifescience Corporation (234080.KS)
Pond Technologies Holdings Inc. (PNDHF)
Business
Tibet Rhodiola Pharmaceutical Holding Co. engages primarily in the development, manufacturing, and distribution of pharmaceuticals focused on traditional Chinese medicine and biologics. Its core product portfolio includes capsules, biological preparations, granules, and film-coating agents. The company offers specialized products targeting cardiovascular and cerebrovascular diseases, hepatobiliary conditions, sprains and contusions, rheumatism, rheumatoid arthritis, and common colds. Key branded products include injectable recombinant human brain natriuretic peptides (Neovactin), isosorbide mononitrate extended-release tablets (IMDOR), Nordicom capsules and granules, Xueshan Jinluohan pain relief coatings, Shiweidida capsules, and children's double cleansing granules. Tibet Rhodiola Pharmaceutical primarily operates within China, leveraging the unique climatic conditions of the Tibetan plateau for cultivating Rhodiola rosea, and maintains international sales channels. The company was founded in 1999 and is headquartered in Lhasa, Tibet Autonomous Region, China. Recent major developments include the completion of a strategic shift involving the transfer of a vaccine production line in Shanghai to fixed assets, now used for process optimization research projects. The company maintains an open attitude toward introducing new pharmaceutical varieties, carefully assessing market prospects and pricing before product launches. Financially, Tibet Rhodiola reported a 31.26% year-on-year increase in net income for fiscal 2024, reaching 1.051 billion yuan, alongside continued participation in national centralized pharmaceutical procurement programs. Additionally, Tibet Rhodiola has implemented a share buyback plan authorized for CNY 140 million, reflecting ongoing efforts to optimize shareholder value. The company operates two main segments: pharmaceutical manufacturing and pharmaceutical trading. Tibet Rhodiola serves a broad spectrum of healthcare needs with a focus on natural health and traditional remedies derived from Rhodiola rosea, integrating modern biotechnological advances and sustaining a significant patent portfolio related to proprietary formulations. Its operational footprint is primarily domestic with expanding export activities. Tibet Rhodiola Pharmaceutical Holding remains committed to sustainable practices and product innovation, supported by strategic partnerships with academic institutions to advance research on Rhodiola rosea's therapeutic effects. This detailed corporate profile reflects Tibet Rhodiola Pharmaceutical Holding's status as a leading pharmaceutical entity specializing in Tibetan and Chinese medicine, offering a comprehensive product range aimed at enhancing health outcomes through natural and biologically sourced medicines in the domestic Chinese market and abroad. The company combines traditional medicinal heritage with modern pharmaceutical technologies to maintain its competitive edge and foster business growth in an evolving healthcare landscape.